
    
      PRIMARY OBJECTIVES:

      I. To provide patients with suboptimal engraftment after allogeneic stem cell transplantation
      access to donor - derived, cluster of differentiation (CD34)+ enriched or T-cell depleted
      peripheral blood stem cells isolated by the CliniMACS System.

      OUTLINE:

      Patients undergo CD34+ enriched or T-cell depleted peripheral blood stem cell infusion
      (PBSCT) over 1-3 hours.

      After completion of study treatment, patients are followed up for 100 days.
    
  